Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation

doi:10.5500/wjt.v14.i2.90571

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

(116)

(0)

(11)

(3269)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Transplant. Jun 18, 2024; 14(2): 90571
Published online Jun 18, 2024. doi: 10.5500/wjt.v14.i2.90571

Table 3 Patient, tumor, and treatment characteristics of patients who underwent liver transplantation, n (%)

Variables	TACE	TAE	P value
Number	48	29
Age (yr), median (IQR)	60.5 (55.75, 65.25)	62 (53, 63)	0.458
Male sex	30 (62.5)	19 (65.5)	0.812
Diagnosis			0.385
HCV	37 (77.1)	25 (86.2)
HBV	4 (8.3)	1 (3.4)
Alcohol	3 (6.2)	3 (10.3)
NASH	4 (8.3)	0
Other	0	0
Calculated MELD score, median (IQR)	9 (8, 11.25)	11 (9, 12)	0.109
Pretransplant AFP, median (IQR)	11.7 (4.77, 46)	9.1 (4.4, 31.95)	0.668
Number of lesions			0.704
1	29 (60.4)	16 (55.2)
2	12 (25)	8 (27.6)
3	7 (14.6)	4 (13.8)
≥ 4	0	1 (3.4)
Largest tumor diameter, median (IQR)	2.8 (2.3, 3.8)	3.3 (2.5, 3.6)	0.333
Milan-out	5 (10.4)	8 (27.6)	0.064
Use of PEI	19 (39.6)	15 (51.7)	0.348
Complete pathological response	7 (14.6)	9 (31)	0.145
Vascular invasion	8 (16.7)	4 (13.8)	> 0.99

Milan-out refers to patients beyond the limits of the Milan criteria. TACE: Transarterial chemoembolization; TAE: Transarterial embolization; HCV: Hepatitis-C virus; HBV: Hepatitis-B virus; MELD: Model for End-Stage Liver Disease; PEI: Percutaneous ethanol injection; IQR: Interquartile range; NASH: Non-alcoholic steatohepatitis.

Full Size Table

Citation: Lazzarotto-da-Silva G, Scaffaro LA, Farenzena M, Prediger L, Silva RK, Feier FH, Grezzana-Filho TJM, Rodrigues PD, de Araujo A, Alvares-da-Silva MR, Marchiori RC, Kruel CRP, Chedid MF. Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation. World J Transplant 2024; 14(2): 90571
URL: https://www.wjgnet.com/2220-3230/full/v14/i2/90571.htm
DOI: https://dx.doi.org/10.5500/wjt.v14.i2.90571

Lazzarotto-da-Silva G, Scaffaro LA, Farenzena M, Prediger L, Silva RK, Feier FH, Grezzana-Filho TJM, Rodrigues PD, de Araujo A, Alvares-da-Silva MR, Marchiori RC, Kruel CRP, Chedid MF. Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation. World J Transplant 2024; 14(2): 90571 [PMID: 38947974 DOI: 10.5500/wjt.v14.i2.90571]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.